Morgan Stanley Reiterates Overweight on Cytokinetics, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Cytokinetics (NASDAQ:CYTK) and maintained a $60 price target.
August 04, 2023 | 4:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Cytokinetics and maintained a $60 price target.
The reiteration of an Overweight rating by Morgan Stanley indicates a positive outlook for Cytokinetics. The maintained price target of $60 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100